$1.21
+0.04
(+3.42%)▲
2.48%
Downside
Day's Volatility :3.78%
Upside
1.34%
43.8%
Downside
52 Weeks Volatility :82.2%
Upside
68.32%
Period | Dariohealth Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -20.95% | 6.5% | 0.0% |
6 Months | -50.84% | 7.1% | 0.0% |
1 Year | -67.59% | 9.8% | 0.0% |
3 Years | -92.22% | 14.2% | -20.2% |
Market Capitalization | 35.0M |
Book Value | $2.65 |
Earnings Per Share (EPS) | -1.68 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.67 |
Profit Margin | -282.37% |
Operating Margin TTM | -310.09% |
Return On Assets TTM | -31.39% |
Return On Equity TTM | -71.67% |
Revenue TTM | 19.0M |
Revenue Per Share TTM | 0.63 |
Quarterly Revenue Growth YOY | -18.5% |
Gross Profit TTM | 14.0M |
EBITDA | -56.4M |
Diluted Eps TTM | -1.68 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.45 |
EPS Estimate Next Year | -1.4 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.41 |
What analysts predicted
Upside of 368.6%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.4M | ↑ 43.02% |
Net Income | -17.8M | ↑ 13.09% |
Net Profit Margin | -240.78% | ↑ 63.73% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | ↑ 2.23% |
Net Income | -17.8M | ↓ 0.2% |
Net Profit Margin | -235.04% | ↑ 5.74% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | ↑ 0.22% |
Net Income | -29.0M | ↑ 63.15% |
Net Profit Margin | -382.62% | ↓ 147.58% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 20.5M | ↑ 170.76% |
Net Income | -76.8M | ↑ 164.81% |
Net Profit Margin | -374.21% | ↑ 8.41% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.7M | ↑ 34.82% |
Net Income | -62.2M | ↓ 18.98% |
Net Profit Margin | -224.88% | ↑ 149.33% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.4M | ↓ 26.41% |
Net Income | -54.9M | ↓ 11.79% |
Net Profit Margin | -269.56% | ↓ 44.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 6.8M | ↑ 3.09% |
Net Income | -12.6M | ↓ 24.41% |
Net Profit Margin | -185.3% | ↑ 67.4% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.1M | ↑ 3.77% |
Net Income | 12.4M | ↓ 198.34% |
Net Profit Margin | 175.6% | ↑ 360.9% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.2M | ↓ 12.94% |
Net Income | -16.6M | ↓ 233.66% |
Net Profit Margin | -269.59% | ↓ 445.19% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5M | ↓ 42.82% |
Net Income | 16.9M | ↓ 201.92% |
Net Profit Margin | 480.5% | ↑ 750.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.6M | ↑ 2.79% |
Net Income | -12.0M | ↓ 170.99% |
Net Profit Margin | -331.88% | ↓ 812.38% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 5.8M | ↑ 59.24% |
Net Income | -6.9M | ↓ 42.36% |
Net Profit Margin | -120.13% | ↑ 211.75% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 14.1M | ↑ 102.52% |
Total Liabilities | 5.2M | ↑ 71.22% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 24.6M | ↑ 74.38% |
Total Liabilities | 5.7M | ↑ 9.9% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 35.4M | ↑ 44.11% |
Total Liabilities | 7.3M | ↑ 27.86% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 100.8M | ↑ 184.61% |
Total Liabilities | 15.2M | ↑ 109.79% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 119.2M | ↑ 18.28% |
Total Liabilities | 39.2M | ↑ 157.47% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 96.4M | ↓ 19.13% |
Total Liabilities | 38.2M | ↓ 2.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 119.2M | ↓ 5.65% |
Total Liabilities | 39.2M | ↑ 4.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 108.0M | ↓ 9.38% |
Total Liabilities | 36.0M | ↓ 8.2% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 117.2M | ↑ 8.47% |
Total Liabilities | 38.8M | ↑ 7.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.5M | ↓ 9.09% |
Total Liabilities | 38.5M | ↓ 0.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 96.4M | ↓ 9.5% |
Total Liabilities | 38.2M | ↓ 0.58% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 137.0M | ↑ 42.1% |
Total Liabilities | 58.9M | ↑ 54.09% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.5M | ↑ 8.01% |
Investing Cash Flow | 6.0K | ↓ 102.74% |
Financing Cash Flow | 18.7M | ↑ 39.22% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.7M | ↑ 37.1% |
Investing Cash Flow | -113.0K | ↓ 1983.33% |
Financing Cash Flow | 25.2M | ↑ 34.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.7M | ↑ 12.79% |
Investing Cash Flow | -1.6M | ↑ 1335.4% |
Financing Cash Flow | 27.5M | ↑ 9.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -50.4M | ↑ 184.22% |
Investing Cash Flow | -8.1M | ↑ 401.48% |
Financing Cash Flow | 65.8M | ↑ 138.73% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.8M | ↓ 5.09% |
Investing Cash Flow | -573.0K | ↓ 92.96% |
Financing Cash Flow | 61.9M | ↓ 5.82% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↓ 25.75% |
Investing Cash Flow | -59.0K | ↓ 66.09% |
Financing Cash Flow | 265.0K | ↓ 99.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.8M | ↓ 40.1% |
Investing Cash Flow | -4.4M | ↑ 7293.22% |
Financing Cash Flow | -1.4M | ↓ 624.15% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.6M | ↑ 102.56% |
Investing Cash Flow | 4.2M | ↓ 195.8% |
Financing Cash Flow | 19.4M | ↓ 1499.42% |
Sell
Neutral
Buy
Dariohealth Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dariohealth Corp | 6.36% | -50.84% | -67.59% | -92.22% | -88.17% |
![]() Solventum Corp | 13.4% | -16.71% | -16.71% | -16.71% | -16.71% |
![]() Veeva Systems Inc. | 1.24% | -10.63% | -7.18% | -43.19% | 9.43% |
![]() Ge Healthcare Technologies Inc. | 2.46% | 9.25% | 3.22% | 32.12% | 32.12% |
![]() Healthequity Inc | -3.68% | 3.76% | 26.99% | 6.89% | -2.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dariohealth Corp | NA | NA | 0.0 | -1.45 | -0.72 | -0.31 | NA | 2.65 |
![]() Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
![]() Veeva Systems Inc. | 54.35 | 54.35 | 1.35 | 4.76 | 0.13 | 0.06 | NA | 30.25 |
![]() Ge Healthcare Technologies Inc. | 23.5 | 23.5 | 20.11 | 4.27 | 0.22 | 0.06 | 0.0 | 16.23 |
![]() Healthequity Inc | 85.91 | 85.91 | 2.29 | 2.19 | 0.04 | 0.03 | NA | 24.11 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dariohealth Corp | Buy | $35.0M | -88.17% | NA | -282.37% |
![]() Solventum Corp | Hold | $10.8B | -16.71% | NA | 15.73% |
![]() Veeva Systems Inc. | Buy | $29.8B | 9.43% | 54.35 | 22.34% |
![]() Ge Healthcare Technologies Inc. | Buy | $36.9B | 32.12% | 23.5 | 8.05% |
![]() Healthequity Inc | Buy | $6.9B | -2.18% | 85.91 | 7.71% |
Insights on Dariohealth Corp
Revenue is up for the last 3 quarters, 3.51M → 5.75M (in $), with an average increase of 20.0% per quarter
Netprofit is up for the last 2 quarters, -12.00M → -6.91M (in $), with an average increase of 73.5% per quarter
In the last 1 year, Healthequity Inc has given 27.0% return, outperforming this stock by 94.6%
In the last 3 years, Healthequity Inc has given 6.9% return, outperforming this stock by 99.1%
Nantahala Capital Management, LLC
Appian WAY Asset Management
Y.D. More Investments Ltd
Phoenix Holdings Ltd
Clal Insurance Enterprises Holdings Ltd
Vanguard Group Inc
DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.
Organization | Dariohealth Corp |
Employees | 276 |
CEO | Mr. Erez Raphael |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.21
+3.42%
Keyarch Acquisition Corp
$1.21
+3.42%
Connexa Sports Technologies Inc
$1.21
+3.42%
Us Value Etf
$1.21
+3.42%
First Wave Biopharma Inc
$1.21
+3.42%
Global X Msci Next Emerging
$1.21
+3.42%
Fat Projects Acquisition Corp
$1.21
+3.42%
Capital Link Global Fintech
$1.21
+3.42%
Applied Uv Inc
$1.21
+3.42%